Josephs said he has spent 35 years in the pharmaceutical industry, including 32 years in the CDMO sector. He said he was drawn to Lifecore because significant capacity investments were already in place, the company had a strong quality track record, and the opportunity was to “fill” capacity and improve profitability.The second segment is sterile injectable contract manufacturing, where Lifecore produces sterile injectable products for other pharmaceutical companies across both development and commercial st ...